xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorSilveira, Fernando Tobias-
dc.contributor.authorLainson, Ralph-
dc.contributor.authorSouza, Adelson Alcimar Almeida de-
dc.contributor.authorCampos, Marliane Batista-
dc.contributor.authorCarneiro, Liliane Almeida-
dc.contributor.authorLima, Luciana Vieira Rego-
dc.contributor.authorRamos, Patrícia Karla Santos-
dc.contributor.authorGomes, Claudia Maria de Castro-
dc.contributor.authorLaurenti, Marcia Dalastra-
dc.contributor.authorCorbett, Carlos Eduardo Pereira-
dc.date.accessioned2016-01-26T11:36:40Z-
dc.date.available2016-01-26T11:36:40Z-
dc.date.issued2010-
dc.identifier.citationSILVEIRA, Fernando Tobias. Further evidences on a new diagnostic approach for monitoring human Leishmania (L.) infantum chagasi infection in Amazonian Brazil. Parasitology Research, v. 106, n. 2, p. 377-386, 2010pt_BR
dc.identifier.issn0932-0113-
dc.identifier.urihttp://patua.iec.gov.br/handle/iec/685-
dc.description.abstractThis was a prospective study carried out during a period over 2 years (May/2006-September/2008) with a cohort of 1,099 individuals of both genders, aged 1 year old and older, from an endemic area of American visceral leishmaniasis (AVL) in Pará state, Brazil. The object was to analyze the prevalence and incidence of human Leishmania (L.) infantum chagasi infection as well as the dynamics evolution of its clinical-immunological profiles prior identified: (1) asymptomatic infection (AI); (2) symptomatic infection (SI = AVL); (3) sub-clinical oligosymptomatic infection (SOI); (4) sub-clinical resistant infection (SRI) and; (5) indeterminate initial infection (III). The infection diagnosis was performed by using both the indirect fluorescent antibody test and leishmanin skin test with amastigotes and promastigotes antigens of L. (L.) i. chagasi, respectively. A total of 187 cases of infection were recorded in the prevalence (17 percent), 117 in the final incidence (6.9 percent), and 304 in the accumulated prevalence (26.7 percent), which provided the following distribution into the clinical-immunological profiles: AI, 51.6 percent; III, 22.4 percent; SRI, 20.1 percent; SOI, 4.3 percent; and SI (=AVL), 1.6 percent. The major finding regarding the dynamics evolution of infection was concerned to III profile, from which the cases of infection evolved to either the resistant profiles, SRI (21 cases, 30.8 percent) and AI (30 cases, 44.1 percent), or the susceptible SI (=AVL; 1 case, 1.5 percent); the latter 16 cases remained as III till the end of the study. These results provided the conclusion that this diagnostic approach may be useful for monitoring human L. (L.) i. chagasi infection in endemic area and preventing the high morbidity of severe AVL cases.pt_BR
dc.description.sponsorshipThis research was supported by Evandro Chagas Institute (Health Ministry, Brazil); Tropical Medicine Institute (Federal University of Pará state, Brazil); Wellcome Trust (London); Laboratório de Investigação Médica (LIM)-50 (Hospital de Clínicas (HC)-Faculdade de Medicina (FM)-Universidade de São Paulo (USP, Brazil), and Fundação de Amparo à Pesquisa do estado de São Paulo (FAPESP: 06/56319-1, Brazil)pt_BR
dc.format.mimetypeapplication/pdf-
dc.language.isoengpt_BR
dc.publisherSpringer Verlagpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleFurther evidences on a new diagnostic approach for monitoring human Leishmania (L.) infantum chagasi infection in Amazonian Brazilpt_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryLeishmania infantum / parasitologiapt_BR
dc.subject.decsPrimaryLeishmaniose Visceral / diagnósticopt_BR
dc.subject.decsPrimaryLeishmaniose Visceral / epidemiologiapt_BR
dc.subject.decsPrimaryLeishmania infantum / isolamento & purificaçãopt_BR
dc.subject.decsPrimaryEstudos Prospectivospt_BR
dc.subject.decsPrimaryImunofluorescência / métodospt_BR
dc.subject.decsPrimaryBrasil / epidemiologiapt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMedical School of São Paulo University. Pathology Department. São Paulo, SP, Brazil.pt_BR
dc.creator.affilliationMedical School of São Paulo University. Pathology Department. São Paulo, SP, Brazil.pt_BR
dc.creator.affilliationMedical School of São Paulo University. Pathology Department. São Paulo, SP, Brazil.pt_BR
dc.identifier.doi10.1007/s00436-009-1672-x-


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple